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Abstract
Background: Complicated intra-abdominal infections (cIAIs) are associated with significant morbidity and mortality. The aim of
this study was to describe the clinical characteristics of patients with cIAI in a multicentre study and to develop clinical prediction
models (CPMs) to help identify patients at risk of mortality or relapse.
Methods: A multicentre observational study was conducted from August 2016 to February 2017 in the UK. Adult patients diagnosed
with cIAI were included. Multivariable logistic regression was performed to develop CPMs for mortality and cIAI relapse. The c-statis-
tic was used to test model discrimination. Model calibration was tested using calibration slopes and calibration in the large (CITL).
The CPMs were then presented as point scoring systems and validated further.
Results: Overall, 417 patients from 31 surgical centres were included in the analysis. At 90 days after diagnosis, 17.3 per cent had a
cIAI relapse and the mortality rate was 11.3 per cent. Predictors in the mortality model were age, cIAI aetiology, presence of a perfo-
rated viscus and source control procedure. Predictors of cIAI relapse included the presence of collections, outcome of initial manage-
ment, and duration of antibiotic treatment. The c-statistic adjusted for model optimism was 0.79 (95 per cent c.i. 0.75 to 0.87) and 0.74
(0.73 to 0.85) for mortality and cIAI relapse CPMs. Adjusted calibration slopes were 0.88 (95 per cent c.i. 0.76 to 0.90) for the mortality
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model and 0.91 (0.88 to 0.94) for the relapse model; CITL was 0.19 (95 per cent c.i. 0.39 to 0.12) and  0.01 ( 0.17 to 0.03)
respectively.
Conclusion: Relapse of infection and death after complicated intra-abdominal infections are common. Clinical prediction models
were developed to identify patients at increased risk of relapse or death after treatment, although these require external validation.
Introduction
Complicated intra-abdominal infections (cIAIs) are defined as
intra-abdominal infections that have extended beyond the hol-
low viscus of origin into the peritoneal space and are associated
with either abscess formation or peritonitis1. One in five patients
with cIAI fail treatment2,3, and in high-risk groups such as the
elderly and those with severe sepsis, the mortality rate is up to
50–80 per cent4,5.
Treatment of cIAIs includes source control and administration
of antibiotic therapy. Guidelines6 recommend that source control
procedures should be the least invasive method capable of
obtaining adequate source control, and that antibiotics be limited
to 4–7 days. Despite current recommended treatment strategies,
patients still suffer high rates of relapse and mortality after cIAI
treatment. Additional strategies are therefore required to help
optimize the care of patients with cIAI. Use of clinical prediction
models may be able to optimize care by identifying patients with
the highest risk of cIAI relapse or death. Currently, disease-
specific prediction models for cIAI exist, which are designed to be
used in the perioperative period in patients undergoing source
control, but are rarely used in routine clinical care. These models
identify patients at the greatest risk of death, so that the aggres-
siveness of treatment can be decided early4,7. However, they are
restricted to patients who undergo a source control procedure.
Additionally, they do not predict the risk of relapse, one of the
most common adverse events after cIAI treatment.
The aim of this study was to undertake a multicentre observa-
tional study to describe the population of patients with cIAI in
the UK, clinical prediction models (CPMs) were then developed to
determine the probability of relapse and death in patients with
cIAI, managed with and without source control procedures.
Methods
A multicentre observational study was performed between
August 2016 and February 2017. The study was classed as a ser-
vice evaluation, registered at participating sites, and information
governance approval was obtained. Data were collected prospec-
tively and recorded using ExcelVR (Microsoft, Redmond, WA, USA),
and anonymized before centralization.
Centre eligibility
All hospitals in the UK were eligible to enter patients. Invitations
to participate were distributed via trainee-led, surgical and infec-
tion research collaboratives.
Patient eligibility
Patients were screened prospectively on inpatient wards, includ-
ing ICUs. To reduce bias, investigators were asked, where possi-
ble, to recruit consecutively identified eligible patients. Patients
were included if they were aged 18 years with a confirmed cIAI.
Patients were excluded if they had a cIAI diagnosed within the
previous year, or their cIAI was diagnosed more than 7 days be-
fore screening, to ensure that only primary episodes of cIAI were
included and that included patients were not biased
towards having more complicated disease. Patients were also
excluded if they had primary appendicitis managed surgically,
active necrotizing pancreatitis (not excluding discrete pancreati-
tis infections such as abscesses or infected pseudocysts), primary
(spontaneous) bacterial peritonitis, and continuous ambulatory
peritoneal dialysis peritonitis, as these were considered to be dis-
tinct clinical conditions with specific management protocols.
Outcome measures
The major outcomes assessed were the presence of cIAI relapse
and all-cause mortality, both within 90 days of cIAI diagnosis.
These same outcomes were considered when generating the
CPMs. Additional outcome measures under investigation in-
cluded the duration of hospital stay, time to relapse or death, and
time to clinical improvement.
Definitions
A diagnosis of cIAI was based on: a combination of radiological and
clinical features consistent with cIAI including a fluid collection
and/or perforated viscus, a temperature of 38C or above or less
than 35C, and a neutrophil count greater than 7.5109/l); or intrao-
perative confirmation of an abscess or perforated abdominal viscus.
In addition, the diagnosis was confirmed by a consultant surgeon.
A cIAI relapse could occur only after source control and/or an-
tibiotic therapy to manage the primary cIAI was considered to
have been successful. This would be demonstrated by the cessa-
tion of antibiotics and there being no further source control pro-
cedures planned. The diagnosis of cIAI relapse was made using
the same criteria as a cIAI, but could also include probable cIAI,
where, in the absence of radiological imaging, no other source
was identified and the diagnosis was confirmed by a consultant
surgeon as cIAI relapse.
Change of antibiotic treatment due to clinical failure was
defined as a change of antibiotic therapy where the clinician col-
lecting the data had determined failure of the previous antibiotic
regimen. Where there was failure of primary treatment of
the cIAI, the reason was taken as the main factor to which the
clinician collecting the data attributed responsibility.
Failure of initial management was defined as the requirement
for an additional unplanned source control procedure and/or a
change of antibiotics due to either failure of antibiotics or the
presence of resistance.
Statistical analysis
CPMs were developed in accordance with the TRIPOD statement8.
Demographic, clinical, and treatment characteristics of
patients who died were compared with those who survived; and
details of patients who had a cIAI relapse were compared with
those who did not. Categorical data are presented as proportions.
Continuous data were tested for normality by visual assessment
of the histogram and then summarized as median (i.q.r.) values.
Comparisons were tested using the v2 test (or Fisher’s exact test if
appropriate) for categorical data and the Mann–Whitney U test
for continuous skewed variables.
Multivariable logistic regression was used to develop predic-
tion models to determine which characteristics were associated
with death or cIAI relapse. Variables included in the pool of
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potential predictors were identified a priori based on their clinical
importance and likelihood (based on existing evidence) to affect
outcomes4,9. The variables assessed for potential inclusion in the
models for relapse and mortality were: age, sex, underlying pa-
thology, site of cIAI, presence of perforation, presences of collec-
tion(s), presence of anastomotic leak, and whether there was
failure of initial management. Treatment variables comprising of
duration of antibiotic therapy and type of source control proce-
dure performed were also included.
Missing data in the data set were assumed to be missing at
random. Multiple imputation via chained equations was there-
fore undertaken to account for missing data. A set of 20 imputed
data sets was created using predictive mean matching, with the
outcomes and all variables in the pool of potential prognostic fac-
tors included in the imputation procedure10. The functional form
for continuous variables was assessed via fractional polynomials
within each imputed data set. Diagnostic plots were used to
check the fit of the imputation models11. Variables were selected
for inclusion in the final model within each imputed data set via
backwards selection with a P value of 0.100. Variables that fea-
tured in at least 10 of the 20 imputed models were selected for
the final model. Pooled odds ratios (ORs) and intercepts were cal-
culated according to Rubin’s rule.
Apparent measures of model performance were calculated for
the final multiply imputed model. Discrimination was evaluated
via the c-statistic, and calibration was assessed via calibration
slopes and calibration in the large (CITL). The c-statistics result-
ing from the imputed data set were pooled via robust methods,
and the median of the imputed estimates is therefore pre-
sented12,13. Calibration was also observed via a calibration plot
for each imputed data set separately, and the median of the im-
puted estimates was provided13.
Non-parametric bootstrapping was used to estimate optimism,
and to examine model stability. In each of 500 bootstrap samples,
the entire modelling process, including predictor selection, was re-
peated, and the apparent model performance (calibration and dis-
crimination in the bootstrap sample) was compared with the
performance in the original sample per multiply imputed data set.
The median optimism across all imputed samples was then
used to calculate the optimism-adjusted c-statistic and
optimism-adjusted calibration slope14. Using the latter as a uni-
form shrinkage factor, all the predictor effects in the final devel-
oped model were penalized to account for overfitting15.
The pool of potential predictors for the backwards selection
was any predictor in a final multivariable model for each im-
puted data set (collection, source control, sex, duration of antibi-
otics, perforated viscus, and failure of initial management).
The resulting optimism-adjusted prediction models were then
presented as a point scoring system by assigning integer scores to
the coeffcients16. Validation of the integer score was undertaken by
evaluating discrimination (c-statistic) and calibration (slope and
CITL) for a model containing only the total points scored per person.
Subgroup analysis was performed to determine whether spe-
cific microbiological data (when available) were associated with
particular clinical outcomes.
Statistical analysis was performed using SPSSVR Statistics for
WindowsVR version 22.0 (IBM, Armonk, NY, USA) and R version 3.6.1,
(The R Foundation for Statistical Computing, Vienna, Austria).
Results
Data were collected on a total of 463 patients from 31 hospitals in
the UK. In total, 417 patients were included in the final analysis;
the data provided did not appear to meet the inclusion criteria for
41 patients and five patients died within 72 h of diagnosis. Of the
417 patients, 224 (53.7 per cent) were women, and the mean (s.d.)
age was 62.5 (17.7) years. Diverticular disease and postoperative
complications were the most common underlying aetiologies in
patients with cIAI, accounting for 32.1 and 21.8 per cent of cases
respectively. The most common site of infection was the colorec-
tum (56.6 per cent) (Table 1).
Radiological features of cIAI included perforated viscus
(61.9 per cent), collections (57.7 per cent) and anastomotic leak
(10.1 per cent). Of the 232 patients with collections, 75.9 per cent
had a single abdominal collection on imaging and 24.1 per cent
had multiple collections. The median maximum depth of the
largest collection present was 6.0 (i.q.r. 4.0–8.8) cm (Table 1).
Patient management
Source control data were missing for 1 patient, of the remaining
416 patients: 30.8 per cent of patients (128 of 416) did not undergo
a source control procedure, 14.2 per cent (59 of 416) had percuta-
neous radiologically guided drainage, and 55.0 per cent (229/416)
had a surgical procedure. Surgical resection and proximal diver-
sion was the most frequently performed procedure (101 of 229,
44.1 per cent). A greater proportion of patients who had surgical
source control had a perforated viscus: 72.6 per cent compared
with 44 per cent of patients who had percutaneous drainage and
52.9 per cent of those who had no source control. Patients under-
going percutaneous drainage were more likely to have a collec-
tion (91 per cent versus 42.6 per cent of patients undergoing a
surgical procedure and 68.5 per cent of patients who had no
source control) (Table S1).
The median duration of antibiotic treatment in this cohort
was 12 (i.q.r. 7–18.5) days. Median antibiotic duration exceeded
7 days irrespective of whether or not patients had a source
control procedure. Duration of antibiotic treatment was a
Table 1 Demographics and clinical characteristics of patients
with complicated intra-abdominal infection
No. of patients (n ¼ 417)
Age (years)* 62.5 (17.7)
Sex ratio (F : M) 224 : 193
Site (origin) of cIAI
Colorectum 236 (56.6)







Diverticular disease 134 (32.1)
Postoperative complication 91 (21.8)
Other 77 (18.5)
Perforated peptic ulcer 37 (8.9)
Cancer 30 (7.2)
Inflammatory bowel disease 19 (4.6)
Biliary stones and/or cholecystitis 19 (4.6)
Appendicitis 10 (2.4)
Perforated viscus 231 of 373 (61.9)
Collection present 232 of 402 (57.7)
Single collection 176 of 232 (75.9)
Multiple collections 56 of 232 (24.1)
Depth of biggest collection (cm) (n 5 213)† 6.0 (4.0-8.8)
Anastomotic leak 41 of 406 (10.1)
Values in parentheses are percentages unless indicated otherwise; * values
are mean(s.d.) and † median (i.q.r.). cIAI, complicated intra-abdominal
infection.
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median of 10.5 (7–17) days in those who had a surgical procedure,
14 (10–24.5) days in those who had percutaneous drainage only,
and 12 (8.5–19) days in those who had no source control proce-
dure. Piperacillin–tazobactam and amoxicillin–clavulanic acid
were the antibiotics used most frequently in the treatment of
cIAI (Table S2).
An additional unplanned source control procedure was per-
formed in 55 per cent of patients who relapsed, compared with
9.8 per cent of patients who did not (P < 0.001). Similarly, a
change of antibiotics due to perceived clinical failure was re-
quired in 37 per cent who relapsed, compared with 14.7 per cent
of those who did not (P < 0.001).
Clinical outcomes
Overall, 17.3 per cent of patients (72 of 417) had a cIAI relapse
and 11.3 per cent (47 of 417) died after 72 h (total mortality
including patients who died within 72 h of diagnosis: 52 of 422,
12.3 per cent). The median duration of hospital stay was 17 (i.q.r.
9.0–29.0) days from the date of cIAI diagnosis. The commonest
reported cause of cIAI relapse was failure of source control (44 of
72, 61 per cent,). The median time to improvement (defined as
apyrexial (temperature below 38C) for more than 24 h and white
cell count lower than 11109/l) from date of diagnosis was
7 (3–14) days. Median time to death or cIAI relapse from diagnosis
was 23 (12–51) days and 18 (13–30) days respectively. The mortal-
ity rate in patients who had a cIAI relapse was 11 per cent, com-
pared with 10.3 per cent in those who did not have a cIAI relapse
(P¼ 0.837). Median duration of antibiotic treatment was longer
in patients who survived to day 90 (12 (8–19) days versus
9 (6–14.5) days in those who died; P¼ 0.007). Patients who had a
cIAI relapse had longer antibiotic treatment for the initial cIAI
than those who did not relapse (median 15 (9.75–21.25) versus 11
(7–17) days respectively; P¼ 0.001). Median length of hospital stay
for primary admission with cIAI was longer in patients who re-
lapsed: 29 (15–49) days compared with 15 (8–25) days in those
who did not have a cIAI relapse (P < 0.001). Of patients who had
collections associated with the cIAI, the rate of relapse in those
with multiple collections was 41 per cent (21 of 51) versus 19.6 per
cent (35 of 179) in those with a single collection (P¼ 0.002).
Model development and model performance
measures
Univariable and multivariable models were developed (Table 2;
Tables S3 and S4). After internal validation and imputation, the
models showed good performance. The c-statistic was 0.82 (95
per cent c.i. 0.76 to 0.88) for the model predicting mortality and
0.78 (0.71 to 0.84) for the model predicting relapse. The values
were 0.79 (0.75 to 0.87) and 0.74 (0.73 to 0.85) respectively after
adjusting for model optimism. The calibration plots for the re-
lapse and mortality CPMs are shown in Figs S1 and S2; they show
good agreement between observed and predicted probabilities for
both models. Calibration slopes were 1.00 (95 per cent c.i. 0.71 to
1.32) for mortality and 1.01 (0.75 to 1.28) for relapse. Calibration
slopes adjusted for model optimism were 0.88 (0.76 to 0.90) and
0.91 (0.88 to 0.94) respectively. The CITL was 0.00 (95 per cent c.i.
0.34 to 0.32) for mortality and 0.01 (0.28 to 0.28) for relapse.
After adjustment, the CITL was 0.19 (0.39 to 0.12) and 0.01
(0.17 to 0.03) respectively.
For mortality, the predictors included in the parsimonious
multivariable logistic regression model were age, cIAI due to can-
cer, type of source control procedure performed, and the pres-
ence of perforated viscus (Table 2).
Predictors included in the model for cIAI relapse were pres-
ence of a collection, duration of antibiotic treatment, and
whether or not there was failure of initial treatment (defined as
requiring an additional unplanned source control procedure or a
change of antibiotics due to either failure of antibiotics or pres-
ence of resistance) (Table 2).
The CPMs have been presented using a point scoring system
(Tables 3–6). The scoring system for mortality predicts probabili-
ties between 0.1 and 70.6 per cent, and that for cIAI relapse pre-
dicts probabilities between 0.3 and 52.4 per cent. The scoring
system was also validated. In particular, calibration and discrimi-
nation were evaluated when the model included the integer score
as the only predictor. The c-statistic for mortality was 0.84
(95 per cent c.i. 0.78 to 0.91) and 0.72 (0.65 to 0.79) for relapse.
The CITL was 0.00 (95 per cent c.i. 0.41 to 0.38) and 0.00 (0.30
to 0.29) respectively. These results show good validity for the in-
teger score.
Subgroup analysis
Subgroup analysis of the 273 patients who had samples sent for
microbiological culture found that 7.7 per cent had either an
ESBL or AmpC producing organism and 21.2 per cent had samples
that grew antibiotic-resistant organisms (amoxicillin–clavulanic
acid/piperacillin–tazobactam-resistant or ciprofloxacin-resistant
Enterobacteriaceae, AmpC or extended-spectrum b-lactamase
(ESBL) producers, vancomycin-resistant enterococci and/or
methicillin-resistant Staphylococcus aureus) Data on organisms
were missing for 13 patients. Patients who had antibiotic-
resistant bacteria isolated from clinical samples had increased
rates of cIAI relapse (33.3 per cent versus 19.3 per cent in those
with no antibiotic-resistant bacteria isolated; P¼ 0.031), longer
duration of antibiotic treatment (median 16.5 (i.q.r. 10–29) versus
13 (7–19) days respectively; P¼ 0.003) and longer hospital stay
after cIAI diagnosis (median 26.5 (i.q.r. 14.75–42.25) versus
15 (9–30) days; P< 0.001). The presence of resistant organisms
was not associated with mortality: 17.9 per cent in patients who
died versus 22.8 per cent in survivors (P¼ 0.549).
Discussion
The data collected from this large UK cohort was used to develop
clinical prediction models for cIAI relapse or death in patients
treated for cIAI. These models have been presented as point scor-
ing systems, providing a range of predicted probabilities that al-
low clear differentiation between patients’ risks of relapse and/or
mortality, and so have potential clinical utility with regard to
patient management decisions. These models use routinely col-
lected clinical data and so are able to be used readily in standard
clinical practice. Model performance tests indicated that both
models have good model performance according to discrimina-
tion and calibration tests.
Prognostic scores for cIAIs already exist, but these are used
primarily to predict mortality. The Manheim Peritonitis Index
(MPI) is a disease-specific severity score that has been established
previously to be an effective prognostic marker in patients with
peritonitis7. It is a simple tool to use, and calculates risk of death
based on age, sex, presence of organ failure, presence of malig-
nancy, duration of peritonitis, origin of infection, and type of exu-
date identified during surgery. The use of operative findings in
the MPI score means it is unsuitable for the 30 per cent of
patients with cIAI who do not undergo any source control proce-
dure. In 2015, the World Society of Emergency Surgery (WSES)
validated a sepsis severity score for patients with intra-
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abdominal infection4. A prospective multicentre observational
study found that the WSES score was useful in predicting sur-
vival (mortality rate 0.63 per cent for score 0–3 and 41.7 per cent
for score above 7)4. This model includes sepsis severity, origin of
cIAI, setting of cIAI acquisition, immunosuppression, age,
and time to source control as predictors. Model performance
measures were not reported. These models are generally applied
in research studies, rather than clinically.
In the present study, the observed mortality rate was
11.3 per cent and the rate of cIAI relapse was 17.3 per cent. The
predictors identified for cIAI relapse and those for mortality were
different, with the predictors for mortality comprising largely
non-modifiable risks. cIAI relapse was not associated with signifi-
cantly increased mortality; however, it was associated with anti-
microbial resistance, longer duration of antibiotic treatment, and
increased length of hospital stay.
In this cohort, 7.7 per cent of patients had an ESBL- or AmpC-
producing organism isolated, similar to values reported in a
European cohort17. Antimicrobial resistance was associated
with a near doubling of the relapse rate, from 19.3 per cent to
33.3 per cent. This highlights that ongoing monitoring for the
presence of antimicrobial-resistant bacterial infection should be
considered important in optimizing the care of patients with cIAI.
This study does have limitations. First, the number of out-
come events was small and this restricted the number of varia-
bles included in the pool of potential predictors for the
multivariable logistic regression model. Second, data for several
variables were missing; however, multiple imputation was con-
ducted to mitigate for this. Third, data were collected at a local
level and the validity of the data provided was not audited.
Fourth, some relevant clinical data, such as severity of sepsis,
placement of drains and duration of drainage, were not collected.
Fifthly in the no-relapse group, patients who died were not ex-
cluded from the analysis when developing the relapse model.
However, there were near equal proportions of patients who had
died in the group that had a relapse and the group that did not,
and so the interpretation of the results was deemed appropriate.
Finally, although point scoring systems facilitate the use of pre-
diction models, they are able to provide only approximate predic-
tions of risk compared with the full models, and so are less
accurate16. However, the clinical predictors selected to be in-
cluded in the final models were consistent with those described
in the literature.
Table 3 Scoring system for probability of death after treatment



















cIAI, complicated intra-abdominal infection.
Table 2 Multivariable models adjusted for shrinkage
Predictor Comparison Odds ratio†
Mortality model
Intercept, log odds ratio (s.e.) 7.53(1.10)
Underlying pathology Diverticular disease 1.00 (reference)
Cancer 4.07 (1.58, 10.48)
Postoperative complication 1.30 (0.46, 3.68)
Other 2.04 (0.98, 4.21)
Source control Surgical 1.00 (reference)
Radiological drainage 0.33 (0.08, 1.30)
No source control 1.58 (0.81, 3.09)
Age (years) 23.5–34.4 1.00 (reference)
34.5–55.4 2.80 (1.91, 4.12)
55.5–65.4 7.61 (3.57, 16.22)
65.5–75.4 14.49 (5.34, 39.29)
75.5–85.4 27.59 (8.00, 95.17)
85.5-95.5 52.54 (11.98, 230.49)
Perforated viscus No 1.00 (reference)
Yes 2.40 (0.94, 6.11)
Relapse model
Intercept, log odds ratio (s.e.) 2.30(0.35)
Collection(s) present No 1.00 (reference)
Yes 1.72 (0.93, 3.17)
Duration of antibiotics (days) <5 1.00 (reference)
5–7 4.71 (0.90, 24.59)
8–11 6.82 (0.88, 52.85)
12–17 7.86 (0.87, 70.85)
18–41 8.65 (0.87, 86.37)
>41 8.87 (0.86, 91.07)
Failure of initial management No 1.00 (reference)
Yes 5.27 (2.96, 9.40)
Values in parentheses are 95 per cent c.i. unless indicated otherwise. †Adjusted for shrinkage based on the median optimism-adjusted calibration slope.
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The presented CPMs and subsequent scoring systems have
advantages over existing ones because they provide information
on both the risk of cIAI relapse and mortality. For these scoring
systems, clinical data collected at the point at which manage-
ment of the cIAI has been completed are used to predict out-
comes at the end of treatment for cIAI. Therefore, they can guide
decisions on patient follow-up or the need for further interven-
tion at a clinically relevant time. They are simple to use and
based on easily accessible patient data. Furthermore, they can be
used for all patients who have a cIAI, irrespective of whether they
undergo source control procedures.
This study has highlighted that, in the UK, there is variation in
the management of cIAIs. One-third of patients do not undergo a
source control procedure and durations of antibiotic treatment
are, on average, longer than those recommended in guide-
lines1,18. This is likely due to the high complication rate seen in
this cohort. These prediction models can help identify patients
with a high risk of complications, in whom deviation from guide-
lines may be warranted. Future work will involve the validation
of both prediction models, and their integer score versions, in
external data from existing cIAI studies. After this assessment
of external validity via discrimination and calibration, clinical
utility studies will be considered.
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